
The CHMP has recommended expanding dolutegravir to term newborns weighing at least 2 kg and dolutegravir/lamivudine to children as young as 3 months, and European Commission decisions are expected in Q1 2027.
WHO and HRP highlight new research on HIV communication, STI priorities, and inclusive strategies to strengthen sexual health worldwide.
Observed on September 4, World Sexual Health Day highlights sexual health as an essential component of overall well-being. The World Health Organization (WHO) and its Human Reproduction Programme (HRP) reaffirmed their commitment to advancing sexual health, rights, and prevention across the life course.1






